TwitterRSSFacebookDirectors Blog
  Disorders A - Z:   A    B   C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z

You Are Here: Home  »  Disorders A - Z  »  Farber's Disease  » 

Skip secondary menu

Farber's Disease Press Releases

NINDS Logo thumbnail

National Neurological Disorders and Stroke Advisory Council welcomes four new members
Thursday, Sep 20, 2012
The NINDS announced that four new members have joined its National Advisory Neurological Disorders and Stroke Council: E. Antonio Chiocca, M.D., Ph.D., David B. Goldstein, Ph.D., Byron D. Ford, Ph.D., and Amy Comstock Rick, J.D. The council serves as the principal advisory body to NINDS regarding the institute’s research program planning and priorities.

Four New Members Named to National Neurology Advisory Council
Thursday, Sep 18, 2008
The National Institute of Neurological Disorders and Stroke (NINDS) has appointed four new members to its major advisory panel, the National Advisory Neurological Disorders and Stroke Council. The NINDS, a component of the National Institutes of Health (NIH), is the nation's primary supporter of basic, translational, and clinical research on the brain and nervous system. NINDS Director Story Landis, Ph.D., formally introduced the new members, who will serve through July 2012, at the Council's September 18, meeting.

NIH Symposium Explores Promise of Stem Cell Therapies
Monday, Jul 14, 2008
Stem cells have been hailed as a toolkit to treat a host of diseases, but at an NIH symposium on May 6, researchers said they are still deciphering the toolkit’s instruction manual.

Statins Prevent a "Sticky" Situation in the Formation of Plaques
Wednesday, Mar 9, 2005
Studies have suggested that statins, a class of cholesterol-lowering drugs, may also lower the risk for Alzheimer’s disease (AD). A new study now suggests that some of the beneficial effects of the drug may be derived from a cholesterol-independent activity. This research, performed in mouse cells carrying an AD-causing gene mutation, may help scientists understand the clinical benefits of statins in AD.